Innovative Strategies to Combat Cancer Metastasis
Written on
Understanding MTDH and Its Impact on Cancer
Recent research reveals groundbreaking methods to inhibit cancer metastasis by targeting a specific gene. Identified in 2004, the gene known as MTDH, or metadherin, has been successfully deactivated during trials.
In the early stages of this research, scientists from Princeton University pinpointed the MTDH gene's association with metastatic breast cancer. However, it wasn’t until 2009 that the findings gained significant attention, following a pivotal study by cancer biologist Yibin Kang. This study revealed that MTDH proteins were present in alarmingly high concentrations in 30 to 40% of tumor samples from breast cancer patients compared to normal cells.
Breast cancer, a prevalent and deadly disease, claims millions of lives worldwide every year. Recently, I discussed a promising breast cancer vaccine entering human trials after 12 years of research. Coupled with this recent study, we may be approaching a breakthrough in the fight against cancer.
Over 15 years of dedicated research, Kang and his team have developed a targeted treatment that can effectively disable MTDH in both mice and human tissues. Remarkably, this innovative approach appears to avoid any adverse side effects.
Metastasis—cancer's ability to spread throughout the body—poses a significant threat. The National Cancer Institute reports that while 99% of breast cancer patients survive for five years post-diagnosis, the survival rate drops drastically to 29% if the cancer has spread. The severity of metastatic breast cancer is underscored by its role in over 40,000 annual deaths in the U.S. alone.
Enhancing Treatment Responses
“Our research identified a range of chemical compounds that could significantly improve the efficacy of chemotherapy and immunotherapy in metastatic breast cancer models. These compounds show significant therapeutic promise.”
~ Minhong Shen, Lead Author
In animal testing, researchers discovered various chemical compounds that boost chemotherapy and immunotherapy effectiveness in metastatic breast cancer. They also created a small, drug-like molecule that can counteract the harmful effects of cancer. Even though many early-stage cancers can be treated successfully with surgery and other methods, there are frequent recurrences, often manifesting as metastatic relapses years later.
Previous studies indicated that the MTDH gene correlates with poor patient outcomes. In 2014, the research team published findings demonstrating that MTDH is crucial for the growth and spread of cancer. Mice lacking the MTDH gene grew normally and, critically, exhibited significantly fewer tumors that did not metastasize when they developed breast cancer.
Targeting Broader Cancer Types
“This gene is vital across numerous cancer types, and by altering just one amino acid, we can eradicate its tumor-promoting effects. It’s a remarkably pure approach that exemplifies the beauty of biochemistry and genetics.”
~ Yibin Kang, Lead Researcher
Interestingly, the implications of this research extend beyond breast cancer. Kang's team found similar results in prostate, lung, and colorectal cancers. Other studies corroborated these findings in liver cancer and various other malignancies. Researchers uncovered that the crystal structure of MTDH displays two projections that connect with another protein, SND1.
By disrupting this connection, they aimed to neutralize MTDH's harmful influence. To achieve this, they meticulously searched through a library of compounds at Princeton’s Department of Chemistry, ultimately identifying a molecule capable of occupying one of the two critical binding sites.
Our immune system is designed for defense, not proactive offense; if it cannot identify a cell as a threat, it cannot act. The MTDH-SND1 interaction suppresses the signals that alert the immune system to the presence of cancer cells. The team is working on refining the compound to improve its affinity and reduce the necessary dosage. Preliminary results have been encouraging, and they anticipate commencing human trials within the next 2 to 3 years.
Complete Research was published [1, 2] in the Journal of Nature.
This video discusses how researchers are targeting a specific gene to hinder the spread of lung cancer, showcasing the innovative approaches being explored in cancer treatment.
Here, experts delve into the complexities of targeting cancer pathways, particularly the role of epigenetics in advancing cancer therapies.